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Abstract: The spectre of antimicrobial resistance looms very large indeed in the 21st century; the supply
of efficacious conventional drugs is short and not guaranteed, for various reasons. It is time to look
elsewhere for answers and for protocols which might be used in tandem with our diminishing arsenal
in order to protect vital drugs. This could bridge the gap before new development in conventional
antimicrobial therapy occurs, or might be a longer-term solution, particularly in the area of infectious
disease prophylaxis (conventional-sensitive or -resistant). Reliable and safe protocols have been
developed for the use of photoantimicrobials in this respect, offering much greater coverage, in terms
of the microbial target, than Fleming ever imagined.
Keywords: antimicrobial drug resistance; infection control; infectious disease prophylaxis; methylene
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1. The Age of Resistance
Among the furore concerning our problems with increasing antimicrobial resistance (AMR),
there is a thread, usually termed ’The rise of the Superbug’ or something similar, which appears to
be regarded as some sort of highly organised, separatist political movement, rather than the organic
expression of evolution that it is. Selective pressure as an evolutionary driver is well understood,
so there should be no need to lionise the result.
However, given that microbes capable of dealing with our current antimicrobial armoury with
such efficiency exist, what should we do about them? Admittedly, there are initiatives aimed at
countering the problem and pronouncements by those governing healthcare, i.e., The Chief Medical
Officer and Lord O’Neill in the UK, and the Centers for Disease Control and Prevention (CDC), UN,
and WHO on the broader stage [1]. However, this is recognised as a complex problem requiring much
more than scientific endeavours for its solution.
It is established that we should decrease the exposure of the microbiome to antimicrobial drugs by
prescribing only when necessary, whether for human or animal diseases, with bad examples including
the prescription of antibiotics for viral illnesses and antibiotic use in agricultural growth promotion.
Equally, the global distribution of drugs must be addressed so that self-medication via uncontrolled
supply might also be stopped.
Clearly, there are difficult – and in some cases, perhaps impossible – tasks to be addressed, but in
one area, i.e., the development of new antimicrobial agents, there should be clarity and a concentration
of efforts.
When Alexander Fleming made reference to bacterial drug resistance in his Nobel Prize acceptance
speech [2], he was reporting laboratory and clinical findings, rather than providing the underlying
mechanisms, as these were as yet undiscovered. The penicillins in use at the time, V and G, would have
presented β-lactamase-type capabilities. In later years, this would include penicillin-binding proteins
and extended-spectrum β-lactamases, but each of these mechanisms is successful—as is the case with
resistance mechanisms against other conventional antimicrobials—because of the single mode/single
site of antimicrobial action approach which has predominated throughout the ‘antibiotic era’.
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2. Fighting Resistance
The great danger in constructing a response to global drug resistance is that we are attempting to
broaden our current antimicrobial arsenal using the same approach, i.e., restricted usage to slow the
onset. New biomolecular targets are, of course, desirable, but these are only likely to provide longevity
if they offer multiplicity, preferably in both the target site and the mode of attack of the resulting drug
candidates. Clearly, this is not a simple or inexpensive undertaking.
However, there is a further point to consider, i.e., is there a general wish to fight the drug-resistance
threat scientifically, or rather, merely to discover/develop new antimicrobial drugs of the same type,
to be employed in the same way? Most scientific reviews and media coverage seem to imply the
latter, with the majority of articles/programmes covering the search for replacement antibiotics, such as
teixobactin [3], and only a tiny fraction being dedicated to other methods, usually biological, such as
vaccination or the use of bacteriophages [4]. The search for these new replacement agents has the
same rationale as that of 70 years earlier, i.e., compounds produced by microorganisms for chemical
defence against other microorganisms, only in different areas of the globe, or using alternative culturing
methods (e.g., teixobactin). Given that we have been spoiled by the ease with which conventional
antimicrobial agents are administered, as well as their general availability, it is unsurprising that
maintaining the status quo is so desirable. Antimicrobial stewardship clearly means a departure from
this situation, and given support (and cooperation) from all sides, can at least cause some arrest in the
development of resistant microbes [5].
It is clear that several pharmaceutical houses have withdrawn from the fight, usually citing the
enormous costs involved in developing new drugs and the relative paucity of return, which puts greater
pressure on those that remain. This should be seen as an opportunity for others (including public
funders), but will only be attractive to the commercial sector if the cost basis is made more manageable.
3. Alternative Approaches
However, there are less expensive approaches which would involve agents which are already
available and approved by relevant regulatory bodies. The antiseptics, such as the quaternary
ammonium compounds (QACs), and related bisbiguanides, such as the chlorhexidine salts, are well
known and have been in use since before the Second World War. Similarly, dye-based therapeutics
such as the flavines and methylene blue were widely used anti-infectives until the middle of the
20th century.
The modern scientist might consider these compounds to be crude and old fashioned. However,
the situation in 21st-century infection control is worsening rapidly, with nightmare figures predicted for
the numbers of deaths due to resistant microbial infection (10 million per year by 2050, according to the
O’Neill Report). In recent years, there have been various published studies under the heading of ‘Old
Drugs for New Bugs’, which usually show recovered activity, e.g., for tetracyclines, aminoglycosides,
etc., against relevant pathogens implicated in AMR as a result of the drugs’ original withdrawal
implemented several years before. Such studies normally reflect the down-regulation of pertinent
resistance mechanisms during the intervening period.
Reintroducing, or rather repurposing, the compounds proposed above would have to involve
more selective use. Given that systemic disease cannot be treated with antiseptics due to the fact
that the internal concentrations required would be too high, and thus toxic for human or animal use,
localised disease offers a more suitable and achievable goal. This may seem to be something of an
underachievement, but provided at the right time and employed in the right way, this method may be
a life-saver. This is particularly relevant with the dyes noted above, when they are used in conjunction
with light activation, causing the production of reactive oxygen species (ROS) in situ.
A useful example here would be that of suspected bacterial tonsillitis. Typically, this would be
treated with a short course of amoxicillin, which might or might not work, depending on the resistance
profile of the (presumed) causative bacteria. Since the antibacterial formulation is orally administered,
much of the flora of the alimentary canal will thus be provided with a dose sufficient to kill a fraction
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of the susceptible population, leaving the resistant cohort unharmed and ready to take over the space
thus liberated. This selective pressure obviously increases the resistant population, but the resulting
physical spread of ‘new’ bacteria into areas normally occupied by commensals can also lead to illness
due to the toxins they release. An extreme instance of this is Clostridioides difficile-associated diarrhoea,
a manifestation of bacterial overgrowth in the colon following extended broad-spectrum antibacterial
use [6]. Such an outcome would be unusual following straightforward tonsillitis treatment, but upset
stomachs caused by a similar mechanism, particularly in juvenile patients, are not.
Given that the intended infection in tonsillitis is localised to the oropharynx, spreading the dose
of the antibacterial throughout the body like this may seem somewhat contradictory, but this has been
the standard therapy for around 80 years.
There is a further problem with this approach in that most conventional antibacterial drugs act
against growing and dividing cells, rather than the resting/quiescent population, which means that
killing or inactivating sufficient numbers may require a period of time, rather than being immediate.
Similarly, small populations of persister cells also exist in each new generation which are resistant to
conventional drugs [7].
Conversely, the direct application of antiseptics to the oropharynx, as a spray, gargle, or lozenge,
locally kills bacteria directly, with little or no effect on the remaining microbiome. This approach could
employ either conventional antiseptics, such as benzalkonium chloride or chlorhexidine digluconate,
which are employed at high concentrations and act principally via membrane and enzyme disruption [8],
or a photosensitiser, such as methylene blue, activated by red light.
3.1. Photoantimicrobials
Of the two methods, the use of conventional antiseptics appears to offer a less complicated route,
requiring no light activation. However, the production of ROS by photosensitisers offers a more
efficient, rapid, and broad-spectrum kill at much lower concentrations. This is also important with
respect to the pathogen class, as detailed below. Given the nonspecific modes of action entailed,
both conventional antiseptics and photoantimicrobials will, of course, also inactivate viruses and
yeasts, unlike conventional antibacterial drugs.
Consequently, this direct approach offers a rapid solution to bacterial or viral tonsillitis which
neither uses valuable conventional antibacterial drugs nor adds to the selective pressure for resistance
development among the microbiota normally associated with conventional therapy.
For a relatively simple disease presentation, such as tonsillitis, there should be little reason against
a proper introduction of this approach. The arguments against the utilisation of photosensitisers
usually involve facts, e.g., that methylene blue is a coloured, staining material and it requires light
activation for significant antimicrobial effects to be achieved. This is insurmountable, i.e., tissue staining
is transient and the application of light to the back of the throat is no more invasive than a routine dental
examination. However, it is fair to say that the employment of photoantimicrobials would represent
a considerable change in anti-infective practice. The question remains whether those involved in
delivery can be persuaded to make the change in view of the advantages over the conventional therapy
outlined above.
Tonsillitis is normally a simple, self-limiting illness, but it can progress to much more serious
conditions, such as pneumonia, meningitis, and septicaemia [9]. Obviously, the clearance of bacterial
infection at the stage of tonsillitis (or otitis media, laryngitis, etc.) is preferable, as opposed to dealing
with a life-threatening disseminated disease. However, a failing battery of conventional antibacterial
drugs means that such progressions will become more common, and the possibility of replacing
conventional therapy at this stage with one which neither suffers from nor leads to resistance should
thus be attractive.
The use of a photoantimicrobial approach for transmission inhibition is similarly
attractive. Methylene blue has been in use for methicillin-resistant Staphylococcus aureus (MRSA)
photodecolonisation for around a decade in Vancouver [10] where elective patients are routinely
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treated with a local application (methylene blue + red light) to the nostrils, with impressive subsequent
decreases in postoperative MRSA infections. Such an approach could be used prophylactically to avoid
the spread of infection among close communities (student accommodation, military establishments,
and prisons), and has considerable potential against both viral (‘flu, coronavirus (COVID)) and bacterial
(meningitis) outbreaks.
3.2. ‘Acceptable’ Alternatives?
Given that dye-based therapeutics were established before the First World War, QACs in the
1930s and photoantimicrobials a quarter of a century ago, it must be asked why these approaches
are not currently employed more directly in infection control protocols. It is clear that they are not
really being considered for future mainstream use, at least in aﬄuent regions, since they are never
mentioned as part of the group of ‘alternative’ approaches to fighting AMR which is now sometimes
listed in government/Non-Government Organisation sources. However, since this listing is very new
in such documents, perhaps it reflects a grudging admission that there is any option at all outside
the conventional route. Since the alternatives usually given are biologicals, i.e., vaccines and phage
therapy, this hardly constitutes scientific adventure, and may, in any case, be too specific for the general,
broad-spectrum coverage of infectious disease which will be required.
4. A New ‘Penicillin’?
The irony of the current situation regarding the non-uptake—indeed, the non-consideration—of
photoantimicrobials is, of course, lost on the huge majority of the population. This is perhaps
unavoidable, given the continuing pre-eminence of the penicillin myth in popular culture and, by
extension, the unassailable position of ‘antibiotics’ in modern infection control. Particularly with
cationic photosensitisers, a truly antimicrobial capability in the face of a rapidly elevating resistance
crisis is available. Descendants of Fleming’s mould broth, such as the 21st -century carbapenems,
are now routinely nullified by resistance mechanisms developed as a result of β-lactam prophylaxis,
or other misuse. Not only does cationic methylene blue kill bacteria which expresses carbapenemase
capability (of any type), but it may also be used prophylactically against colonisation by such bacteria
without promoting resistance development. Furthermore, protection against viral infection in this way
would also both nullify rapid viral mutation rates, as seen, e.g., with COVID-19, and maintain efficacy
regardless of strain and antigenic shift/drift such as between serotypes in influenza.
Funding: This research received no external funding.
Conflicts of Interest: The author declares no conflict of interest.
References
1. Horton, R. AMR – the end of modern medicine? Lancet 2019, 393, 624. [CrossRef]
2. Fleming, A. Nobel Prize Lecture, December 11th 1945. Available online: https://www.nobelprize.org/prizes/
medicine/1945/fleming/lecture/ (accessed on 10 January 2020).
3. McCarthy, M.W. Teixobactin: A novel anti-infective agent. Exp. Rev. Anti-Infect. Ther. 2019, 17, 1–3.
[CrossRef] [PubMed]
4. Baker, S.J.; Payne, D.J.; Rappuoli, R.; De Gregorio, E.D. Technologies to address antimicrobial resistance.
PNAS 2018, 115, 12887–12895. [CrossRef] [PubMed]
5. Dyar, O.J.; Huttner, B.; Schouten, J.; Pulcini, C. What is antimicrobial stewardship? Clin. Microbiol. Infect.
2017, 23, 793–798. [CrossRef] [PubMed]
6. Garg, S.; Mirza, Y.R.; Girotra, M.; Kumar, V.; Yoselevitz, S.; Segon, A.; Dutta, S.K. Epidemiology of
Clostridium difficile-associated disease (CDAD): A shift from hospital-acquired infection to long-term care
facility-based infection. Dig. Dis. Sci. 2013, 58, 3407–3412. [CrossRef] [PubMed]
7. Wozniak, A.; Grinholc, M. Combined Antimicrobial Activity of Photodynamic Inactivation and
Antimicrobials–State of the Art. Front. Microbiol. 2018, 9, 930. [CrossRef] [PubMed]
Antibiotics 2020, 9, 117 5 of 5
8. Kuyyakanond, T.; Quesnel, L.B. The mechanism of action of chlorhexidine. FEMS Microbiol. Lett. 1992,
100, 211–215. [CrossRef] [PubMed]
9. Singh, K.; Nordstrom, T.; Morgelin, M.; Brant, M.; Cardell, L.O.; Riesbeck, K. Haemophilus influenzae resides
in tonsils and uses immunoglobulin D as an evasion strategy. J. Infect. Dis. 2014, 209, 1414–1428. [CrossRef]
[PubMed]
10. Loebel, N.; Andersen, R.; Dawson, T.; Cross, C. Antimicrobial photodynamic therapy: A decade of
development and clinical study. In Photodynamic Medicine, from Bench to Clinic; Kostron, H., Hasan, T., Eds.;
Royal Society of Chemistry: London, UK, 2016; pp. 519–548.
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
